Pharmacological EZH2 inhibition was proven to be effective in the treatment of entities with activating EZH2 mutations such as Diffuse Large Cell B-Cell as well as Follicular Lymphoma in phase II clinical trials [41,42]. The gene discussed is EZH2; the disease is follicular lymphoma.